MTSR - NASDAQ
Metsera, Inc.
$70.50
+0.0000%Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity. The company was incorporated in 2022 and is headquartered in New York, New York.
At a Glance
Live SnapshotMetsera, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Metsera, Inc. Balance Sheet
MTSR • NASDAQ
| Metsera, Inc. Balance Sheet | Dec 2024 | Dec 2023 |
|---|---|---|
ASSETS | ||
CURRENT ASSETS | ||
352.4M | 75.2M | |
352.4M | 75.2M | |
2.1M | 848K | |
4.6M | 761K | |
359.1M | 76.8M | |
NON-CURRENT ASSETS | ||
1.4M | 27K | |
21.9M | 22.2M | |
68.5M | 69.4M | |
90.4M | 91.6M | |
0.0 | 410K | |
91.9M | 92M | |
451M | 168.8M | |
LIABILITIES | ||
CURRENT LIABILITIES | ||
21.2M | 3.6M | |
20.8M | 2.7M | |
392K | 946K | |
11.7M | 1.7M | |
8.4M | 0.0 | |
714K | 0.0 | |
25.3M | 14.9M | |
67.3M | 20.2M | |
NON-CURRENT LIABILITIES | ||
7.8M | 17.7M | |
87.9M | 32.5M | |
96.3M | 50.2M | |
1.4M | 0.0 | |
163.6M | 70.3M | |
SHAREHOLDERS' EQUITY | ||
540.9M | 143.7M | |
2.5M | 85K | |
-257.1M | -48M | |
1.2M | 2.8M | |
287.4M | 98.5M | |
287.4M | 98.5M | |
SUMMARY | ||
451M | 168.8M | |
9.8M | 0.0 | |
-342.6M | -75.2M | |
105,371,473 | 105,371,473 |
SEC Filings
MTSR - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2025 N/A | November 13, 2025 | November 12, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 12, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 10, 2025 | November 07, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 06, 2025 | November 03, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 04, 2025 | November 03, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 03, 2025 | November 03, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 03, 2025 | October 31, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 30, 2025 | October 29, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 29, 2025 | September 29, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 22, 2025 | September 21, 2025 | 2025 |
Related Guides
Continue your MTSR research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.